<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) characterized by multilineage cytopenias and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> but lacking an increase in blasts, with no Auer rods or <z:mp ids='MP_0000220'>monocytosis</z:mp>, do not exactly fit any of the categories of the French-American-British (FAB) classification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and are often diagnosed as <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), or 'unclassifiable' <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It has been suggested that these 'unclassifiable' cases form a distinct subset with a clinical behavior more like that of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) than that of RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, but few studies have been undertaken that characterize this group </plain></SENT>
<SENT sid="2" pm="."><plain>We compared the clinical, hematologic, morphologic and cytogenetic features of 18 such patients - for whose disease we propose the designation 'refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>' (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>) - to those of 42 patients meeting the FAB criteria for RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> (14 patients) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (28 patients) </plain></SENT>
<SENT sid="3" pm="."><plain>Our results show that cytopenias in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> are more severe than those in RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, but are similar to those in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0012132'>Erythroid hyperplasia</z:hpo> and dyserythropoiesis are the main findings in bone marrow specimens of RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, but the major features in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> are multilineage proliferation and <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, which, except for the lack of increased blasts resemble the findings in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Only 1/14 patients (7%) with RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> had an abnormal karyotype, whereas <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> resembled <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in terms of the frequency (41 vs 50%, respectively) and type of karyotypic lesions </plain></SENT>
<SENT sid="6" pm="."><plain>Abnormalities of chromosomes 5 and 7 (excluding del(5q) as an isolated finding) or complex aberrations were seen only in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>. in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, the median survival was 24 months, with a 4-year survival rate of48 +/- 13%, intermediate between the findings in RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> (107 months and 77 +/- 12%, respectively) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (18 months and 27 +/- 9%, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>Our data indicate that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> is a distinct subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, with an unfavorable clinical outcome </plain></SENT>
<SENT sid="8" pm="."><plain>The designation 'refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>' emphasizes the differences between such cases and the primarily dyserythropoietic, indolent subgroups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, such as RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> </plain></SENT>
</text></document>